PROTHELIA INCORPORATED Employee Directory
BiotechnologyMassachusetts, United States11-50 Employees
Prothelia Incorporated is a biotechnology research company based in Boston, Massachusetts, focusing on the development of recombinant human Laminin-111 (rhLAM-111) for the treatment of congenital muscular dystrophy type 1A (MDC1A), also known as Merosin deficiency or LAMA2 deficiency. By pursuing a targeted therapy for this specific muscular dystrophy, the company operates within a niche of therapeutic development for muscular and congenital disorders. The organization, positioned in the biotechnology research sector, appears to serve specialized clinical research and development needs, likely collaborating with medical and scientific stakeholders involved in rare muscular diseases. Located in the Boston area, the company is part of a regional ecosystem known for life sciences and employs a workforce that reflects a focused research and development operation.